Alimera reports 13% increase in quarterly revenue

Alimera Sciences reported an increase in consolidated net revenue of 13% from $9.8 million to $11.1 million in the third quarter of 2018, according to a press release.

Revenue in the U.S. rose 20% from $7.1 million to $8.5 million, while international revenue remained flat at approximately $2.6 million.

The company posted a net loss of $3.5 million compared with a net loss of $5.3 million in 2017’s third quarter. The net income per common share was $0.40 compared with a net loss per common share of $0.08 a year ago.

General and administrative costs increased by $100,000 to $3.4 million, sales and marketing costs decreased from $6 million to $5.5 million, and research, development and medical affairs costs decreased to $2.8 million compared with $5.4 million.

Alimera Sciences reported an increase in consolidated net revenue of 13% from $9.8 million to $11.1 million in the third quarter of 2018, according to a press release.

Revenue in the U.S. rose 20% from $7.1 million to $8.5 million, while international revenue remained flat at approximately $2.6 million.

The company posted a net loss of $3.5 million compared with a net loss of $5.3 million in 2017’s third quarter. The net income per common share was $0.40 compared with a net loss per common share of $0.08 a year ago.

General and administrative costs increased by $100,000 to $3.4 million, sales and marketing costs decreased from $6 million to $5.5 million, and research, development and medical affairs costs decreased to $2.8 million compared with $5.4 million.